9月8日，医疗创新与实践发展学会（HIPDS）在香港总部召开新闻发布会，正式发布2025版《亚太医疗创新发展白皮书》。这是学会连续第三年发布该白皮书，报告全面分析了亚太地区医疗创新的现状、趋势和挑战。
2025版白皮书在编制过程中广泛收集了来自亚太地区12个主要经济体的数据和案例，走访调研了超过200家医疗和研究机构，访谈了100余位医学领域的专家学者。报告由HIPDS学术事务部主笔，医学研究与发展中心（MRDC）和临床实践评估委员会（CPEC）提供了大量的数据支持和专业分析。
白皮书指出，亚太地区医疗创新在过去一年中呈现出三大显著趋势：第一，人工智能在医学领域的应用进入快速落地阶段，尤其在医学影像诊断、临床决策支持和药物发现方面取得了实质性突破。据统计，亚太地区2024年获批的AI辅助医疗器械数量较2023年增长了67%。第二，精准医疗从概念走向实践，基于基因组学的个体化诊疗方案在肿瘤、罕见病和慢性病管理等领域的应用日益广泛。第三，数字健康生态系统加速构建，远程医疗、数字疗法和健康大数据平台获得了持续的政策支持和资本投入。
同时，白皮书也指出了亚太地区医疗创新面临的三大瓶颈：监管协调不足——各国和地区的医疗技术审批标准和流程差异较大。资金缺口明显——从基础研究到临床应用的转化阶段仍面临显著的资金断层。人才结构性短缺——具备跨学科背景和转化研究能力的复合型人才供给不足。
本版白皮书的一大亮点是首次引入了"创新转化指数"（ITI）评估体系。该指数从研发投入、成果产出、转化效率、政策环境和人才储备五个维度，对亚太12个主要经济体的医疗创新转化能力进行了量化评估。结果显示，日本、澳大利亚和新加坡位列前三，中国大陆排名第四但在成果产出和研发投入方面增速最快。
白皮书全文约12万字，包含80余张数据图表和30个深度案例分析。中英文版本均可在HIPDS官方网站免费下载。
On September 8, HIPDS held a press briefing at its Hong Kong headquarters and officially released the 2025 Asia-Pacific Healthcare Innovation Development White Paper. This is the third consecutive year that the Society has published the white paper.
The 2025 edition draws on data and cases from 12 major economies in the Asia-Pacific. The research team visited more than 200 medical and research institutions and interviewed over 100 experts and scholars. The report was prepared by the HIPDS Academic Affairs Department with data support and professional analysis from the Medical Research and Development Centre and the Clinical Practice Evaluation Committee.
The white paper identifies three major trends. First, artificial intelligence applications in medicine are moving rapidly into practical deployment, especially in medical imaging, clinical decision support, and drug discovery. Second, precision medicine is shifting from concept to practice, with genomic-based individualized diagnosis and treatment expanding in oncology, rare diseases, and chronic disease management. Third, digital health ecosystems are developing quickly, supported by policy and capital investment.
The report also notes ongoing challenges, including uneven regional development, insufficient clinical validation, data governance pressure, and the shortage of interdisciplinary talent. HIPDS will use the white paper as a basis for future research support, academic exchange, and policy discussion.